Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
| العنوان: | Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes |
|---|---|
| المؤلفون: | Maria G. Montez, Henry A. Glick, Brenda Montgomery, Louise Hesson, Patricia Feeney, J. Bruce Redmon, Michael S. Lawlor, Stephen P. Glasser, Stephanie Connelly, Alain G. Bertoni, Frank L. Greenway |
| المصدر: | Diabetes Care |
| بيانات النشر: | American Diabetes Association, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Physical fitness, Type 2 diabetes, Overweight, law.invention, Randomized controlled trial, Weight loss, law, Risk Factors, Diabetes mellitus, Weight Loss, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Obesity, Risk factor, Exercise, Antihypertensive Agents, Original Research, Aged, Hypolipidemic Agents, Advanced and Specialized Nursing, business.industry, Clinical Care/Education/Nutrition/Psychosocial Research, Middle Aged, medicine.disease, Surgery, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Emergency medicine, Female, medicine.symptom, business, Energy Intake |
| الوصف: | OBJECTIVE To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45–76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 ± 1.8 for the ILI group and 3.6 ± 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 ± 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 ± 1.7) at lower cost ($154/month) (P < 0.001). CONCLUSIONS At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk. |
| اللغة: | English |
| تدمد: | 1935-5548 0149-5992 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e42eb61f8f1627d54aaadce7b2f584e http://europepmc.org/articles/PMC2875414 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....4e42eb61f8f1627d54aaadce7b2f584e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19355548 01495992 |
|---|